INT28060

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.66
First Reported 1989
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 48
Total Number 49
Disease Relevance 37.31
Pain Relevance 3.79

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
coronary artery 2
plasma 2
blood 2
heart 2
muscle 1
Hdlcl1 (Mus musculus)
Pain Link Frequency Relevance Heat
fluoxetine 13 99.24 Very High Very High Very High
Paracetamol 8 97.60 Very High Very High Very High
Angina 20 96.84 Very High Very High Very High
Bioavailability 6 92.76 High High
Inflammation 72 91.56 High High
Pain 45 90.24 High High
Endocannabinoid 35 88.16 High High
withdrawal 19 86.12 High High
alcohol 25 84.32 Quite High
ischemia 18 83.64 Quite High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 1892 100.00 Very High Very High Very High
Coronary Heart Disease 132 100.00 Very High Very High Very High
Toxicity 36 99.72 Very High Very High Very High
Coronary Artery Disease 149 99.28 Very High Very High Very High
Obesity 260 99.22 Very High Very High Very High
Weight Loss 31 99.22 Very High Very High Very High
Increased Venous Pressure Under Development 399 99.08 Very High Very High Very High
Myocardial Infarction 69 98.64 Very High Very High Very High
Atherosclerosis 333 98.56 Very High Very High Very High
Metabolic Syndrome 258 98.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The drug lowered systolic blood pressure and body mass index to a significant level (p < 0.05) and increased HDL-cholesterol only slightly along with marginal improvement in left ventricular ejection fraction in stable angina patients.
Positive_regulation (increased) of HDL-cholesterol in blood associated with angina, obesity and disorder of lipid metabolism
1) Confidence 0.66 Published 1994 Journal J Assoc Physicians India Section Abstract Doc Link 7741874 Disease Relevance 0.92 Pain Relevance 0.53
At laboratory level there was an elevation of HDL-cholesterol and lowering of serum lipids values (cholesterol and triglycerides) in both groups.
Positive_regulation (elevation) of HDL-cholesterol associated with disorder of lipid metabolism
2) Confidence 0.45 Published 1996 Journal Obes. Res. Section Abstract Doc Link 8946439 Disease Relevance 0.57 Pain Relevance 0.49
Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDL-cholesterol, and lipid sub-profiles.
Positive_regulation (increases) of HDL-cholesterol associated with disorder of lipid metabolism
3) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Abstract Doc Link PMC2291331 Disease Relevance 0.54 Pain Relevance 0
Intervention trials using a fibrate to increase HDL-cholesterol have also yielded significant anti-atherosclerotic benefits or improvements in cardiovascular event rates (Frick et al 1987; Cashin-Hemphill et al 1990; Rubins et al 1999).
Positive_regulation (increase) of HDL-cholesterol associated with atherosclerosis and disorder of lipid metabolism
4) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 0.98 Pain Relevance 0
Mean increases in HDL-cholesterol at study end in the Niaspan® 1000 mg and 1500 mg groups were 19% and 24%, respectively, which were significant (p < 0.05) compared with small changes observed on placebo.
Positive_regulation (increases) of HDL-cholesterol associated with disorder of lipid metabolism
5) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 0.82 Pain Relevance 0.03
Larger increases in HDL-cholesterol were observed with Niaspan® – lovastatin 1000 mg/40 mg (+17%) and 2000 mg/40 mg (+32%), relative to atorvastatin 40 mg (+6%) or simvastatin 40 mg (+7%).
Positive_regulation (increases) of HDL-cholesterol associated with disorder of lipid metabolism
6) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 0.38 Pain Relevance 0
Increases in HDL-cholesterol after addition of Niaspan® to the regimen were similar to those for Niaspan® monotherapy, described above, with mean increases of 23% with the 1000 mg dose and 27% for the 2000 mg dose.
Positive_regulation (Increases) of HDL-cholesterol associated with disorder of lipid metabolism
7) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 0.52 Pain Relevance 0
Dose-related increases in HDL-cholesterol occurred with increases in the dose of Niaspan® and additional reductions in LDL-cholesterol occurred when Niaspan® 2000 mg was combined with lovastatin 40 mg, relative to this dose of statin plus placebo.
Positive_regulation (increases) of HDL-cholesterol associated with disorder of lipid metabolism
8) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 0.53 Pain Relevance 0
Thus, the ARBITER 2 and ARBITER 3 trials demonstrate that increased HDL-cholesterol during treatment with Niaspan® and a statin was associated with clinically significant anti-atherogenic benefits in patients with coronary artery disease.


Positive_regulation (increased) of HDL-cholesterol in coronary artery associated with coronary artery disease and disorder of lipid metabolism
9) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 1.05 Pain Relevance 0
Mean increases from baseline in HDL-cholesterol in men and women were 22.4% and 28.1%, respectively, with corresponding decreases in triglycerides of ?
Positive_regulation (increases) of HDL-cholesterol associated with disorder of lipid metabolism
10) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 1.36 Pain Relevance 0.04
Larger increases in HDL-cholesterol were observed in patients with HDL-cholesterol <1.0 mmol/L (40 mg/dL) at baseline.
Positive_regulation (increases) of HDL-cholesterol associated with disorder of lipid metabolism
11) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 0.50 Pain Relevance 0
One year of treatment with Niaspan® in ARBITER 2 increased mean HDL-cholesterol from 1.0 mmol/L (39 mg/dL) to 1.2 mmol/L (47 mg/dL; p < 0.001), and decreased triglycerides from 1.7 mmol/L (154 mg/dL) to 1.5 mmol/L (134 mg/dL; p = 0.009), while no change in either parameter occurred in the placebo group.
Positive_regulation (increased) of HDL-cholesterol associated with disorder of lipid metabolism
12) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 0.41 Pain Relevance 0
Reductions in LDL-cholesterol were similar between treatments, but Niaspan®-rosuvastatin, and Niaspan® – atorvastatin regimens were more effective in increasing HDL-cholesterol and in reducing triglycerides, compared with simvastatin in combination with ezetimibe or rosuvastatin monotherapy (Figure 3).
Positive_regulation (increasing) of HDL-cholesterol associated with disorder of lipid metabolism
13) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 0.23 Pain Relevance 0.03
A number of studies have demonstrated clinically significant cardiovascular benefits from pharmacologic intervention to increase levels of HDL-cholesterol in patients with coronary artery disease.
Positive_regulation (increase) of HDL-cholesterol in coronary artery associated with coronary artery disease and disorder of lipid metabolism
14) Confidence 0.43 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 0.94 Pain Relevance 0
In contrast, treatment with all doses of Niaspan® was associated with significant increases in HDL-cholesterol relative to placebo, up to a maximum increase of about 30% relative to baseline at doses of 2500–3000 mg.
Positive_regulation (increases) of HDL-cholesterol associated with disorder of lipid metabolism
15) Confidence 0.31 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 0.27 Pain Relevance 0
Mean increases in HDL-cholesterol were similar in patients with and without the metabolic syndrome (36% vs 32%), as were reductions in LDL-cholesterol (?
Positive_regulation (increases) of HDL-cholesterol associated with metabolic syndrome and disorder of lipid metabolism
16) Confidence 0.31 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 0.81 Pain Relevance 0
A pooled analysis of Framingham and three other major North American trials (the Lipid Research Clinics Prevalence Mortality Follow-up Study, the Coronary Primary Prevention Trial and the Multiple Risk Factor Intervention Trial) showed that for each decrease in HDL-cholesterol of 0.03 mmol/L (1 mg/dL), the risk of coronary heart disease increased by 2% in men and by 3% in women (Gordon et al 1989).
Positive_regulation (increased) of HDL-cholesterol in heart associated with coronary heart disease and disorder of lipid metabolism
17) Confidence 0.31 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291331 Disease Relevance 1.07 Pain Relevance 0
Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly.
Positive_regulation (increasing) of HDL-cholesterol associated with disorder of lipid metabolism
18) Confidence 0.29 Published 2007 Journal Vascular Health and Risk Management Section Abstract Doc Link PMC2291331 Disease Relevance 0.41 Pain Relevance 0
In intervention trials it was without exception possible to influence the development of atherosclerosis by a reduction of the LDL-cholesterol and an increase in HDL-cholesterol and to reduce complications like myocardial infarction, sudden cardiac death, angina or heart failure.
Positive_regulation (increase) of HDL-cholesterol in heart associated with angina, increased venous pressure under development, myocardial infarction and disorder of lipid metabolism
19) Confidence 0.19 Published 2000 Journal Herz Section Abstract Doc Link 10992996 Disease Relevance 0.74 Pain Relevance 0.10
Pioglitazone shows favourable changes in lipid parameters like decrease of serum-triglycerides and increase of HDL-cholesterol, while rosiglitazone temporarily increases LDL-cholesterol.
Positive_regulation (increase) of HDL-cholesterol associated with disorder of lipid metabolism
20) Confidence 0.11 Published 2010 Journal The Open Neurology Journal Section Body Doc Link PMC2923338 Disease Relevance 0.82 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox